Skip to main content
Signal8
Launch Terminal

Natera, Inc. (NTRA)

Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.

Sector: Services-Medical Laboratories

Industry: Medical - Diagnostics & Research

Natera, Inc. logo

Natera, Inc.

NASDAQ:NTRAHealthcare
-4.98%$414.30
AH$414.30+0.00%vs close
Mkt Cap$59.72B
Float135.16M
O/S144.14M
Vol
$ Vol
RVOL
Inst Own94.8%
SI4.3%
Earnings
Dilution
Natera, Inc. logoNASDAQ:NTRA$414.30-4.98%
Phase Distribution
36 lead-sponsored trials·11 active·14 completed
Phase 41
Not applicable35
(41 more as collaborator)
Status Overview
Not yet recruiting4
Recruiting7
Active, not recruiting4
Completed14
Stopped5
Unknown2

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 4
    Terminated

    Impact of Parental Support on Pregnancy Outcomes (IPSO) Trial- Day 3 Preimplantation Genetic Screening (PGS) With Day 5 Fresh Transfer

    24 Chromosome Aneuploidy Screening with Parental Support

    Preimplantation Gentic Screening (PGS), In Vitro Fertilization (IVF) +1

    Enrollment
    59
    Start
    Sep 2010
    Primary Completion
    Apr 2013
    Completion
    Apr 2013
    NCT01194531
  • Not applicable
    Completed

    Concurrent Single Gene and 24 Chromosome Aneuploidy Preimplantation Genetic Diagnosis (PGD)

    preimplantation diagnosis

    Any Single Gene Disorder (Cystic Fibrosis, Tay-Sachs)

    Enrollment
    56
    Start
    Nov 2009
    Primary Completion
    Mar 2014
    Completion
    Mar 2014
    NCT01023048
  • Observational
    Completed

    Clinical Use of Parental Support To Detect Single Gene Mutations

    Preimplantation Genetic Diagnosis

    Single Gene Disorders

    Enrollment
    240
    Start
    Sep 2010
    Primary Completion
    Jun 2013
    Completion
    Jun 2013
    NCT01197872
  • Observational
    Terminated

    Prenatal Non-invasive Aneuploidy Test Utilizing SNPs Trial

    Blood Draw

    Trisomy 13, Trisomy 18 +2

    Enrollment
    937
    Start
    Jan 2012
    Primary Completion
    Apr 2014
    Completion
    Mar 2023
    NCT01545674
  • Observational
    Completed

    Collection of Maternal Blood Samples for Development of Non-invasive Prenatal Diagnostic Testing

    Blood draw

    Pregnancy Following IVF With PGS/PGD

    Enrollment
    16
    Start
    Feb 2012
    Primary Completion
    May 2012
    Completion
    Aug 2013
    NCT01546324
  • Observational
    Completed

    Non-invasive Prenatal Diagnostic Validation Study

    Blood draw, Cheek swab/Saliva Sampling

    Chromosome 13 Aneuploidy, Chromosome 18 Aneuploidy +3

    Enrollment
    1,781
    Start
    Sep 2011
    Primary Completion
    Apr 2013
    Completion
    Apr 2013
    NCT01574781
  • Observational
    Withdrawn

    Multi-disease Carrier Screening Test Validation

    Blood draw

    Spinal Muscular Atrophy (SMA), Carrier Screening +1

    Enrollment
    0
    Start
    Aug 2012
    Primary Completion
    Jun 2013
    Completion
    -
    NCT01663584
  • Observational
    Completed

    Development of Non-invasive Prenatal Screening Test for Microdeletions Based on Fetal DNA Isolated From Maternal Blood

    -

    Trisomy 21, Trisomy 18 +3

    Enrollment
    1,059
    Start
    Nov 2012
    Primary Completion
    Oct 2020
    Completion
    Oct 2020
    NCT01852708
  • Observational
    Completed

    Development of Non-invasive Prenatal Test for Microdeletion and Other Genetic Syndromes Based on Cell Free DNA

    -

    Microdeletion Syndromes, Trisomy 21 +3

    Enrollment
    216
    Start
    Oct 2012
    Primary Completion
    Jun 2019
    Completion
    Aug 2019
    NCT02109770
  • Observational
    Completed

    Multiple Gestation Study

    -

    Trisomy 13, Trisomy 18 +2

    Enrollment
    354
    Start
    Mar 2013
    Primary Completion
    Mar 2019
    Completion
    Mar 2019
    NCT02278536
  • Observational
    Completed

    High Risk Multiple Gestation Study

    -

    Trisomy 13, Trisomy 18 +2

    Enrollment
    99
    Start
    Aug 2014
    Primary Completion
    Dec 2018
    Completion
    Mar 2019
    NCT02278874
  • Observational
    Completed

    SNP-based Microdeletion and Aneuploidy RegisTry (SMART)

    -

    22q11 Deletion Syndrome, DiGeorge Syndrome +9

    Enrollment
    20,960
    Start
    Apr 2015
    Primary Completion
    Jun 2020
    Completion
    Jun 2020
    NCT02381457
  • Observational
    Terminated

    Natera Ovarian Cancer Detection Assay

    -

    Adnexal Mass

    Enrollment
    12
    Start
    Dec 2017
    Primary Completion
    Nov 2019
    Completion
    Dec 2019
    NCT03485651
  • Observational
    Completed

    Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection

    -

    Transplant Rejection, Allograft Rejection +1

    Enrollment
    110
    Start
    Sep 2018
    Primary Completion
    Aug 2024
    Completion
    Aug 2024
    NCT03984747
  • Observational
    Active, not recruiting

    The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive)

    Prospera

    Kidney Transplant Rejection

    Enrollment
    5,000
    Start
    Nov 2019
    Primary Completion
    Oct 2026est.
    Completion
    Oct 2027est.
    NCT04091984
  • Observational
    Unknown status

    BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer

    -

    Colorectal Cancer, Colon Cancer

    Enrollment
    1,788
    Start
    Apr 2020
    Primary Completion
    Sep 2025est.
    Completion
    Sep 2025est.
    NCT04264702
  • Observational
    Completed

    BESPOKE Study of ctDNA Guided Immunotherapy

    -

    Colorectal Cancer, Melanoma +1

    Enrollment
    290
    Start
    May 2021
    Primary Completion
    Dec 2023
    Completion
    Mar 2024
    NCT04761783
  • Observational
    Completed

    Verification of Risk Assignment for Whole Chromosome Using SNP-based NIPT in Vanishing Twin Pregnancies

    -

    Vanishing Twin, Trisomy 21 +2

    Enrollment
    136
    Start
    Jul 2021
    Primary Completion
    Nov 2023
    Completion
    Nov 2023
    NCT05004337
  • Not applicable
    Withdrawn

    Donor-Derived Cell-free DNA to DETect REjection in Cardiac Transplantation

    Prospera Transplant Assessment, Endomyocardial biopsy

    Heart Transplant Failure and Rejection

    Enrollment
    0
    Start
    Jan 2023est.
    Primary Completion
    Jan 2025est.
    Completion
    Jan 2026est.
    NCT05081739
  • Observational
    Active, not recruiting

    LAMBDA 002 (Lung Registry) Study

    Prospera

    Lung Transplant Rejection

    Enrollment
    154
    Start
    Nov 2022
    Primary Completion
    Aug 2026est.
    Completion
    May 2027est.
    NCT05170425
  • Observational
    Active, not recruiting

    Prospera Test Evaluation in Cardiac Transplant (ProTECT)

    -

    Heart Transplant Rejection

    Enrollment
    411
    Start
    Oct 2021
    Primary Completion
    Oct 2026est.
    Completion
    Jun 2027est.
    NCT05205551
  • Observational
    Completed

    Development of Non-invasive Cell-free DNA to Supplant Invasive Biopsy in Heart Transplantation

    Prospera

    Heart Transplant

    Enrollment
    147
    Start
    Dec 2022
    Primary Completion
    Oct 2024
    Completion
    Oct 2024
    NCT05309382
  • Observational
    Completed

    Clinical Utility of the Addition of a SNP-based NIPT Zygosity Determination in Twin Pregnancy Management.

    -

    Twin to Twin Transfusion Syndrome, Pregnancy Complications +1

    Enrollment
    137
    Start
    Oct 2021
    Primary Completion
    May 2023
    Completion
    May 2023
    NCT05312814
  • Not applicable
    Unknown status

    Renasight Clinical Application, Review and Evaluation (RenaCARE) Study

    Renasight

    Kidney Diseases

    Enrollment
    1,720
    Start
    Jun 2021
    Primary Completion
    Aug 2025est.
    Completion
    Aug 2025est.
    NCT05846113
  • Not applicable
    Active, not recruiting

    A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy

    The Prospera™ Test

    Heart Transplant Failure and Rejection

    Enrollment
    250
    Start
    Jun 2024
    Primary Completion
    Feb 2027est.
    Completion
    Feb 2027est.
    NCT06414603

1-25 of 36

Search ClinicalTrials.gov for “Natera”